MDCO - The Medicines Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.00
+0.20 (+1.01%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close19.95
Open19.94
Bid19.76 x 3200
Ask30.05 x 1300
Day's Range19.15 - 20.01
52 Week Range16.69 - 41.57
Volume666,796
Avg. Volume1,342,113
Market Cap1.472B
Beta (3Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-3.52
Earnings DateFeb 19, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.85
Trade prices are not sourced from all markets
  • MoneyShow2 days ago

    Top Picks 2019- The Medicines Company MDCO

    2018 was a difficult year for The Medicines Company (MDCO) with the stock languishing as biotech investors looked elsewhere; in our view, 2019 will be a turnaround year, making this our top speculative pick, asserts biotech specialist John McCamant, editor of The Medical Technology Stock Letter.

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Medicines Co.

    # Medicines Co ### NASDAQ/NGS:MDCO View full report here! ## Summary * Bearish sentiment is high ## Bearish sentiment Short interest | Negative Short interest is extremely high for MDCO with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MDCO. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $3.37 billion over the last one-month into ETFs that hold MDCO are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire13 days ago

    The Medicines Company Announces 5th Review of Un-blinded Data and Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase 3 Trials

    With full commercial rights in all geographies, The Medicines Company is well placed to harness the intrinsic value of inclisiran. To date, more than 2,450 patient-years of inclisiran safety data have been accumulated in the ORION program, a seven-fold (or 2,120 patient-year) increase over the total patient exposure from the ORION Phase 1 and Phase 2 trials. At the time of IDMC review, all patients in Phase 3 trials had received three doses of inclisiran or placebo.

  • Implied Volatility Surging for Medicines Company (MDCO) Stock Options
    Zacks17 days ago

    Implied Volatility Surging for Medicines Company (MDCO) Stock Options

    Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.

  • Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III
    Zacks27 days ago

    Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III

    Mallinckrodt (MNK) and partner NPXe Limited enrol the first patient in the phase III study on xenon gas for inhalation (XENEX) for Post Cardiac Arrest Syndrome (PCAS).

  • Benzinga28 days ago

    Insider Buys Of The Week: Chesapeake Energy, Medicines Company, NuStar Energy

    Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Chesapeake Energy Corporation (NYSE: CHK) saw Chief Executive Officer Robert Lawler, Chief Financial Officer Domenic J. Dell'Osso Jr. and two other insiders add to their stakes this past week. The new The Medicines Company (NASDAQ: MDCO) CEO, Mark Timney, and two other insiders altogether added more than 180,000 shares of this biopharmaceutical company to their stakes this past week.

  • See what the IHS Markit Score report has to say about Medicines Co.
    Markitlast month

    See what the IHS Markit Score report has to say about Medicines Co.

    This means that investors who seek to profit from falling equity prices are currently targeting MDCO. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • GuruFocus.comlast month

    The Medicines Co (MDCO) CEO Mark Timney Bought $499,652 of Shares

    CEO of The Medicines Co (NASDAQ:MDCO) Mark Timney bought 26,863 shares of MDCO on 12/17/2018 at an average price of $18.6 a share.

  • Is The Medicines Company (MDCO) A Good Stock To Buy?
    Insider Monkeylast month

    Is The Medicines Company (MDCO) A Good Stock To Buy?

    A market correction in the fourth quarter, spurred by a number of global macroeconomic concerns and rising interest rates ended up having a negative impact on the markets and many hedge funds as a result. The stocks of smaller companies were especially hard hit during this time as investors fled to investments seen as being […]

  • Business Wirelast month

    The Medicines Company Prices $150 Million of Convertible Notes

    The Medicines Company (MDCO) (the “Company”) today announced that it has priced its private offering of $150 million in aggregate principal amount of its convertible senior notes due 2024. The notes will be senior unsecured obligations of the Company and will mature on January 15, 2024, unless earlier converted or repurchased in accordance with their terms. The notes will be convertible prior to October 15, 2023 only upon the occurrence of certain circumstances and will be convertible thereafter regardless of these circumstances, in either case, into cash, shares of the Company’s common stock or a combination thereof, at the Company’s option.

  • Here's Why Shares of The Medicines Company Sank 14.5% Today
    Motley Foollast month

    Here's Why Shares of The Medicines Company Sank 14.5% Today

    Investors aren't happy about the drugmaker's latest capital raise.

  • Business Wirelast month

    The Medicines Company Announces Intention to Offer $150 Million of Convertible Notes

    The Medicines Company (MDCO) (the “Company”) today announced that it proposes to offer $150 million aggregate principal amount of convertible senior notes due 2024, subject to market conditions and other factors. The notes will be convertible, upon certain conditions, into cash, shares of the Company’s common stock or a combination thereof, at the Company’s option. The interest rate, conversion rate, offering price and other terms will be determined by negotiations among the Company and J.P. Morgan Securities LLC, the initial purchaser of the notes.

  • MarketWatchlast month

    The Medicines Co. names Mark Timney CEO effective immediately

    The Medicines Co. said Tuesday it has appointed Mark Timney as chief executive with immediate effect. Timney comes fo the job after stints at Merck & Co., and Purdue Pharmaceuticals, as well as Zeneca Group, ICI Pharmaceuticals and Roussel Labs. he will replace Clive Meanwell, who will serve as chief innovation officer. Shares were not yet active premarket, but have fallen 24% in 2018 through Monday's close, while the S&P 500 has fallen 1.3%.

  • Business Wirelast month

    The Medicines Company Appoints Mark Timney as Chief Executive Officer

    The Medicines Company (MDCO) today announced that its Board of Directors has appointed Mark Timney as the Company’s new Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Timney will succeed Clive Meanwell, M.D., Ph.D., who has been appointed by the Board to serve as Chief Innovation Officer. Alexander Denner, Ph.D., the Chairman of the Board of Directors, stated, “We are pleased to welcome Mark Timney as our new CEO.

  • Medicines Co. (MDCO) Down 11% Since Last Earnings Report: Can It Rebound?
    Zackslast month

    Medicines Co. (MDCO) Down 11% Since Last Earnings Report: Can It Rebound?

    Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • See what the IHS Markit Score report has to say about Medicines Co.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Medicines Co.

    Medicines Co NASDAQ/NGS:MDCO

  • See what the IHS Markit Score report has to say about Medicines Co.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Medicines Co.

    Medicines Co NASDAQ/NGS:MDCO

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MDCO earnings conference call or presentation 8-Nov-18 1:30pm GMT

    Q3 2018 Medicines Co Earnings Call

  • See what the IHS Markit Score report has to say about Medicines Co.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Medicines Co.

    Medicines Co NASDAQ/NGS:MDCO